ABL Diagnostics Société anonyme (EPA:ABLD)

Market Cap	49.95M
Revenue (ttm)	6.23M
Net Income (ttm)	463.36K
Shares Out	16.11M
EPS (ttm)	n/a
PE Ratio	107.81
Forward PE	n/a
Dividend	0.05 (1.61%)
Ex-Dividend Date	Jun 27, 2025

Volume	91
Average Volume	1,908
Open	3.080
Previous Close	3.080
Day's Range	3.000 - 3.100
52-Week Range	2.400 - 8.100
Beta	-1.11
RSI	43.16
Earnings Date	Dec 4, 2025

About EPA:ABLD

ABL Diagnostics Société anonyme provides proprietary molecular biology assays and end-to-end solutions to be used for molecular detection by polymerase chain reaction (PCR) and through DNA sequencing in France and internationally. The company offers genotyping through NGS and sanger sequencing for human immunodeficiency virus, SARS CoV-2, hepatitis-C virus, mycobacterium tuberculosis, and 16S/18S RNA; ultragene assays for viral detection of SARS CoV-2, MonkeyPox, and Clostridium; microbiological specimen transport and collection kits, which inc...

• Industry: Health Information Services
• Sector: Healthcare
• CEO: Chalom Sayada
• Employees: 19
• Stock Exchange: Euronext Paris
• Ticker Symbol: ABLD

Financial Performance

In 2024, EPA:ABLD's revenue was 5.87 million, a decrease of -5.16% compared to the previous year's 6.19 million. Earnings were 285,170, an increase of 424.58%.